Adam M. Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda Bosserman, Charles Vogel, Christopher Seidler, Lixian Jin, Ghulam Warsi, Eliza Argonza-Aviles, John Hohneker, Solveig G. Ericson and Edith A. Perez Final 5-year results of Z-FAST trial Cancer 118
Version of Record online: 10 OCT 2011 | DOI: 10.1002/cncr.26313
Upfront zoledronic acid appears to significantly increase bone mineral density in postmenopausal women with early breast cancer receiving letrozole for 5 years versus delayed zoledronic acid administration. Long-term coadministration of letrozole and zoledronic acid is well tolerated.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field